drugset
drugset / Trial / NCT04217096

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

NCT04217096 ↗

Phase 4 Unknown 40 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

The present study is intended to investigate the efficacy and safety of the patients with confirmed advanced pancreatic cancer after treating with the combination of paclitaxel liposome plus S-1.

Timeline

Start
2020-01-01
Primary completion
2022-09-30
Completion
2023-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel liposome Unknown 175 mg/m2 Intravenous
Subject S-1 Small molecule 40 mg —
Subject S-1 Small molecule 50 mg —
Subject S-1 Small molecule 60 mg —

Indications

pancreatic neoplasm